Toronto stocks finished a quiet session with a modest gain Tuesday following the U.S. Federal Open Market Committee decision to leave the federal funds rate target at 1%, a 45-year low.

The S&P/TSX composite index rose 36.21 points to close at 7,354.02.

The heavily weighted financial stocks rose 0.7% and health-care stocks added a solid 2.9% gain.

Lorus Therapeutics rose 12¢, or nearly 11%, to $1.22 after the company got approval by the U.S. Food and Drug Administration for phase II clinical trials of its lead cancer-fighting drug.

Extendicare jumped $1.34 to $6.24 as the market reacted to the company’s sharp rise in second-quarter earnings.

Royal Bank rose 64¢ to $60.48, while CIBC advance 76¢ to $54.36.

Toronto volume was light as 190 million shares valued at $2.2 billion changed hands. Market momentum was positive as 606 issues advanced and 526 declined.

The junior S&P/TSX Venture composite index closed up 2.81 points at 1,224.95.

Trading was heavy on a volume of 46.0 million shares worth $17.5 million, with 210 advances, 225 declines and 503 issues unchanged.

In New York, stocks surged, boosted by the Fed’s announcement that it would keep U.S. interest rates unchanged.

The Fed warned again about the risk of falling prices and said rates could stay low for “a considerable period.”

The Dow Jones industrial average soared 92.71 points to 9,310.06. The broader S&P 500 added 9.76 points to 990.35. The tech-laced Nasdaq composite index jumped 25.5 points to 1,687.01.

The Canadian dollar finished lower following the Fed decision. The loonie closed at US72.24¢, down slightly from US 72.44¢ at Monday’s North American close.